Thermo Fisher Scientific Financial Statements
NYSE: TMOIndustrialsIndustrial Machinery/ComponentsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Thermo Fisher Scientific revenue and earnings
In fiscal 2025, Thermo Fisher Scientific generated $44.56 billion in revenue, up 3.9% from fiscal 2024, its 2nd consecutive year of revenue growth. Net income was $6.70 billion (+5.8% year over year), for a net margin of 15.0% versus a median of 15.5% in the prior 5 years. Operating margin was 17.4%.
Diluted earnings per share came in at $17.74, up from $16.53. Over the last 5 fiscal years, TMO's revenue has grown at a 6.7% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
Thermo Fisher Scientific income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 44.56B | 42.88B | 42.86B | 44.91B | 39.21B | 32.22B | 25.54B | 24.36B | 20.92B | 18.27B |
| Revenue growth (YoY) | +3.91% | +0.05% | -4.58% | +14.55% | +21.71% | +26.14% | +4.86% | +16.45% | +14.47% | +7.72% |
| Cost of Revenue | — | — | — | — | — | — | — | — | 8.98B | 8.21B |
| Gross Profit | — | — | — | — | — | — | — | — | 11.94B | 10.06B |
| Operating Expenses | — | — | — | — | — | — | — | — | 8.98B | 7.60B |
| Research & Development | 1.40B | 1.39B | 1.34B | 1.47B | 1.41B | 1.18B | 1.00B | 967.00M | 887.00M | 754.00M |
| Selling, General & Admin | 8.73B | 8.60B | 8.45B | 8.99B | 8.01B | 6.93B | 6.14B | 6.06B | 5.50B | 4.97B |
| Operating Income | 7.75B | 7.34B | 6.86B | 8.39B | 10.03B | 7.79B | 4.59B | 3.78B | 2.96B | 2.46B |
| Interest Expense | 1.42B | 1.39B | 1.38B | 726.00M | 536.00M | 553.00M | 676.00M | 667.00M | 592.00M | 469.00M |
| Other Income (Expense) | -12.00M | 12.00M | -65.00M | -104.00M | -694.00M | -76.00M | -70.00M | 9.00M | -20.00M | -13.00M |
| Pretax Income | 7.31B | 7.04B | 6.30B | 7.83B | 8.84B | 7.22B | 4.07B | 3.26B | 2.43B | 2.02B |
| Income Tax | 547.00M | 657.00M | 284.00M | 703.00M | 1.11B | 850.00M | 374.00M | 324.00M | 201.00M | -1.00M |
| Net Income | 6.70B | 6.33B | 6.00B | 6.96B | 7.73B | 6.38B | 3.70B | 2.94B | 2.23B | 2.02B |
| Net Income growth (YoY) | +5.82% | +5.67% | -13.86% | -9.94% | +21.19% | +72.44% | +25.87% | +32.04% | +10.04% | +2.38% |
| EPS (Basic) | 17.77 | 16.58 | 15.52 | 17.75 | 19.62 | 16.09 | 9.24 | 7.31 | 5.64 | 5.12 |
| EPS (Diluted) | 17.74 | 16.53 | 15.45 | 17.63 | 19.46 | 15.96 | 9.17 | 7.24 | 5.59 | 5.09 |
| Shares Outstanding (Basic) | 377.00M | 382.00M | 386.00M | 392.00M | 394.00M | 396.00M | 400.00M | 402.00M | 395.00M | 395.00M |
| Shares Outstanding (Diluted) | 378.00M | 383.00M | 388.00M | 394.00M | 397.00M | 399.00M | 403.00M | 406.00M | 398.00M | 397.00M |
| EBITDA | 8.80B | 8.49B | 7.93B | 9.38B | 10.86B | 8.45B | 5.16B | 6.05B | 4.99B | 4.22B |
| Gross Margin | — | — | — | — | — | — | — | — | 57.09% | 55.05% |
| Operating Margin | 17.38% | 17.11% | 16.00% | 18.69% | 25.57% | 24.19% | 17.99% | 15.53% | 14.15% | 13.45% |
| Net Margin | 15.05% | 14.77% | 13.99% | 15.50% | 19.71% | 19.79% | 14.48% | 12.06% | 10.64% | 11.06% |
This table shows 10 annual periods of Thermo Fisher Scientific's income statement, from FY 2025 back to FY 2016, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow TMO's reporting calendar. What is a income statement?